S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.
about
S100A1 Protein Does Not Compete with Calmodulin for Ryanodine Receptor Binding but Structurally Alters the Ryanodine Receptor·Calmodulin Complex.Pathophysiological mechanism and therapeutic role of S100 proteins in cardiac failure: a systematic review.Raf kinase inhibitor protein: lessons of a better way for β-adrenergic receptor activation in the heart.Emerging molecular therapies targeting myocardial infarction-related arrhythmias.
P2860
S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
S100A1 DNA-based Inotropic The ...... nodine Receptor 2 Dysfunction.
@ast
S100A1 DNA-based Inotropic The ...... nodine Receptor 2 Dysfunction.
@en
type
label
S100A1 DNA-based Inotropic The ...... nodine Receptor 2 Dysfunction.
@ast
S100A1 DNA-based Inotropic The ...... nodine Receptor 2 Dysfunction.
@en
prefLabel
S100A1 DNA-based Inotropic The ...... nodine Receptor 2 Dysfunction.
@ast
S100A1 DNA-based Inotropic The ...... nodine Receptor 2 Dysfunction.
@en
P2093
P2860
P356
P1433
P1476
S100A1 DNA-based Inotropic The ...... anodine Receptor 2 Dysfunction
@en
P2093
Andreas Seitz
Hugo A Katus
Julia Ritterhoff
Karsten Peppel
Kristin Spaich
Patrick Most
Rainer H A Fink
Sven T Pleger
Walter J Koch
P2860
P304
P356
10.1038/MT.2015.93
P577
2015-05-25T00:00:00Z